Mednet Logo

In patients with recurrent MSI-H endometrial cancer on immunotherapy with pembrolizumab, when do you discontinue therapy?

Do you stop therapy at 2 years or continue until progression of disease?
Community PollStarted

How long do you typically continue treatment of recurrent dMMR endometrial cancer with pembrolizumab?

22 physicians have voted

Join Mednetto vote and see how they answered.

1 Answer
Mednet Member
Mednet MemberInvited Expert
Gynecologic Oncology · University of Alabama at Birmingham
Answered on

If they have no evidence of disease on their scan, I stop at 2 years.

Join for free or sign in to see the full answer